17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
September 2025 in “Journal of the Pakistan Medical Association” Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.
2 citations
,
June 2020 in “Clinical Journal of Gastroenterology” Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
49 citations
,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
4 citations
,
May 2019 in “Sultan Qaboos University Medical Journal” Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
2 citations
,
October 2018 in “Archives of Dermatological Research” Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
May 2023 in “Frontiers in Endocrinology” Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
December 2014 in “Journal of Biomedical Research” Recombinant thymosin β4 promotes blood vessel growth and reduces muscle damage.
5 citations
,
June 2019 in “Open Forum Infectious Diseases” Six African American women experienced hair loss after switching to a new HIV medication.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.